Novartis Settles with Henrietta Lacks Estate Over Unauthorized HeLa Cell Use

The settlement between Novartis and the estate of Henrietta Lacks represents a pivotal moment in the intersection of corporate accountability and medical ethics. This agreement, finalized in February 2026, addresses the decades-long use of the 'immortal' HeLa cell line, which was harvested from Lacks without her knowledge or consent in 1951. For the pharmaceutical industry, the resolution of this case is more than just a legal closure; it is a signal that the era of ignoring the ethical origins of legacy biological materials is coming to an end.

Henrietta Lacks, a Black woman treated for cervical cancer at Johns Hopkins Hospital, unknowingly provided the cells that would become the first human cell line to reproduce indefinitely in a laboratory setting. These cells, known as HeLa, have been foundational to modern medicine. They were instrumental in developing the polio vaccine, advancing gene mapping, and creating treatments for cancer, HIV/AIDS, and COVID-19. While these breakthroughs have saved millions of lives and generated billions of dollars in revenue for the global pharmaceutical sector, Lacks and her descendants were left in the dark for decades, neither compensated nor recognized for her involuntary contribution.

“

The settlement between Novartis and the estate of Henrietta Lacks represents a pivotal moment in the intersection of corporate accountability and medical ethics.

The legal strategy employed by the estate, led by prominent civil rights attorney Ben Crump, focused on the concept of 'unjust enrichment.' The lawsuit argued that Novartis continued to profit from HeLa cells long after the unethical nature of their acquisition became public knowledge. By commercializing products developed using the HeLa line, the estate contended that Novartis was effectively trafficking in stolen biological material. This legal theory bypasses traditional statutes of limitations by focusing on the ongoing profits generated by the cells rather than the initial act of taking them in 1951.

This settlement follows a landmark 2023 agreement between the Lacks estate and Thermo Fisher Scientific, suggesting a domino effect within the industry. Novartis’s decision to settle rather than face a protracted public trial indicates a strategic move to mitigate reputational risk. In an era where Environmental, Social, and Governance (ESG) metrics are increasingly scrutinized by investors, a public battle over the exploitation of a Black woman’s body would have been catastrophic for the company’s brand. The settlement allows Novartis to move forward while acknowledging the historical context of its research materials.